Novo Nordisk AS's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 72.32.
Novo Nordisk AS's Days Inventory for the
three
months ended in Mar. 2026 was 338.92.
Novo Nordisk AS's Days Payable for the
three
months ended in Mar. 2026 was 963.88.
Therefore, Novo Nordisk AS's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was -552.64.
Novo Nordisk AS (HAM:NOVA) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Novo Nordisk AS Cash Conversion Cycle Related Terms
Novo Nordisk AS Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:NOVA vs LLY, JNJ, ABBV: Cash Conversion Cycle Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Novo Nordisk AS's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Conversion Cycle of -552.64 mean?
Novo Nordisk AS (HAM:NOVA) has a Cash Conversion Cycle of -552.64 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Cash Conversion Cycle too high?
Novo Nordisk AS's current Cash Conversion Cycle is -552.64. Overall, Novo Nordisk AS has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Cash Conversion Cycle compare to LLY and JNJ?
Novo Nordisk AS's Cash Conversion Cycle of -552.64 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.82, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Novo Nordisk AS and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Nordisk AS's current Cash Conversion Cycle is -552.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (HAM:NOVA) is currently considered Significantly Undervalued. The stock's GF Value™ is €120.48, compared to a current price of €41.86 — trading 65.3% below its estimated fair value. The current Cash Conversion Cycle is -552.64. Novo Nordisk AS's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Novo Nordisk AS (HAM:NOVA), the current Cash Conversion Cycle is -552.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (HAM:NOVA) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of €41.86 is trading 65.3% below its estimated GF Value™ of €120.48.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for HAM:NOVA:
Cash Conversion Cycle: -552.64
GF Value™: €120.48 vs. price of €41.86 (65.3% below fair value)
No single metric tells the full story. See the HAM:NOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
84GF Score
Get the complete analysis for HAM:NOVA
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:NOVA has been successfully added to your 
